On Friday, Ocugen Inc (OCGN) stock saw a modest uptick, ending the day at $0.71 which represents no change from the prior close of of $0.71. The stock opened at $0.72 and touched a low of $0.7 during ...

On Thursday, Ocugen Inc (OCGN) stock saw a decline, ending the day at $0.71 which represents a decrease of $-0.02 or -2.74% from the prior close of $0.73. The stock opened at $0.74 and touched a low ...

Shares of Ocugen Inc. OCGN slid 1.91% to $0.72 Thursday, on what proved to be an all-around rough trading session for the ...

Ocugen, Inc. has announced the commencement of its Phase 1 clinical trial for OCU200, targeting diabetic macular edema (DME). The trial, which has begun dosing its first patient, aims to evaluate ...

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and ...

Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering ...